Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zymeworks Inc (ZYME)
NASDAQ:ZYME
Zymeworks (ZYME) Stock Price & Analysis
463 Followers
ZYME Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.02 - $13.14
Previous Close$8.51
Volume986.35K
Average Volume (3M)631.32K
Market Cap
$606.55M
Enterprise Value$286.64M
Total Cash (Recent Filing)$345.05M
Total Debt (Recent Filing)$25.13M
Price to Earnings (P/E)―
Beta0.57
Next Earnings
Aug 01, 2024EPS Estimate
-$0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.79
Shares Outstanding70,704,890
10 Day Avg. Volume628,834
30 Day Avg. Volume631,321
Standard Deviation0.16
R-Squared0.14
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.48
Price to Sales (P/S)35.13
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.68
Enterprise Value/Gross Profit3.77
Enterprise Value/Ebitda-2.58
Forecast
1Y Price Target
$13.60Price Target Upside59.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Zymeworks News
PremiumCompany Announcements
Zymeworks’ Novel Cancer Drug ZW171 Gets FDA Nod
PremiumCompany Announcements
Zymeworks Advances with Cancer Drug in China
PremiumCompany Announcements
Zymeworks to Showcase Innovations at Investor EventsBulls Say, Bears Say
Bulls Say
Clinical DataZanidatamab elicited a 41.3% objective response rate with a median duration of response of 14.9 months.
Financial MilestonesZymeworks is entitled to receive an $8M milestone payment and also remains eligible to receive up to $164M based on additional milestones plus royalties on product sales generated in the Asia Pacific region.
Regulatory ApprovalsZW171 Investigational New Drug application receives timely FDA clearance.
Bears Say
Financial PerformanceZymeworks recorded a net loss of $0.42 per share—wider than the previously forecasted net loss of $0.31 per share.
Market PerformanceYTD, shares are down -13% vs. XBI's -2% largely because there are few clinical catalysts in ZYME's pipeline and potentially some worry about the BTC and GEA market opportunities for zani given Enhertu's tumor agnostic approval for HER2+ solid tumors.
Safety ConcernsFrom a safety standpoint, 20.7% of patients experienced a G3+ TRAE, with 3.4% of patients having a confirmed G3+ cardiac event.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ZYME FAQ
What was Zymeworks Inc’s price range in the past 12 months?
Zymeworks Inc lowest stock price was $6.01 and its highest was $13.14 in the past 12 months.
What is Zymeworks Inc’s market cap?
Currently, no data Available
When is Zymeworks Inc’s upcoming earnings report date?
Zymeworks Inc’s upcoming earnings report date is Aug 01, 2024 which is in 29 days.
How were Zymeworks Inc’s earnings last quarter?
Zymeworks Inc released its earnings results on May 02, 2024. The company reported -$0.42 earnings per share for the quarter, missing the consensus estimate of -$0.322 by -$0.098.
Is Zymeworks Inc overvalued?
According to Wall Street analysts Zymeworks Inc’s price is currently Undervalued.
Does Zymeworks Inc pay dividends?
Zymeworks Inc does not currently pay dividends.
What is Zymeworks Inc’s EPS estimate?
Zymeworks Inc’s EPS estimate is -$0.42.
How many shares outstanding does Zymeworks Inc have?
Zymeworks Inc has 70,704,890 shares outstanding.
What happened to Zymeworks Inc’s price movement after its last earnings report?
Zymeworks Inc reported an EPS of -$0.42 in its last earnings report, missing expectations of -$0.322. Following the earnings report the stock price went up 2.222%.
Which hedge fund is a major shareholder of Zymeworks Inc?
Among the largest hedge funds holding Zymeworks Inc’s share is Farallon Capital Management, L.L.C.. It holds Zymeworks Inc’s shares valued at 17M.
---
Zymeworks Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.60 (59.81% Upside)
$13.60 (59.81% Upside)
Blogger Sentiment
Bullish
ZYME Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 146.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.4%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.93%
12-Months-Change
Fundamentals
Return on Equity
-27.64%
Trailing 12-Months
Asset Growth
-7.82%
Trailing 12-Months
Company Description
Zymeworks Inc
Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani, and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.
---
ZYME Company Deck
---
ZYME Earnings Call
Q1 2024
0:00 / 0:00
---
ZYME Stock 12 Month Forecast
Average Price Target
$13.60
▲(59.81% Upside)
Technical Analysis
Best Analysts Covering ZYME
1 Year
1 Year Success Rate
10/14 ratings generated profit
1 Year Average Return
+36.59%
reiterated a buy rating 2 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +36.59% per trade.
---